Ionis Pharmaceuticals IONS Equity securities
Equity securities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNi.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's equity securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's equity securities?
- Ionis Pharmaceuticals (IONS) reported equity securities of $77.77M in Q1 2026.
- How has Ionis Pharmaceuticals's equity securities changed year-over-year?
- Ionis Pharmaceuticals's equity securities increased by 76.3% year-over-year, from $44.11M to $77.77M.
- What is the long-term trend for Ionis Pharmaceuticals's equity securities?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's equity securities has grown at a 2.2% compound annual growth rate (CAGR), from $50.53M to $55.22M.
- What does equity securities mean?
- The total market value of all stock investments held by the company.
- How do you interpret equity securities?
- An increase suggests the company is expanding its strategic footprint or that its existing equity holdings are growing in value.
- How does equity securities compare across companies?
- Varies significantly based on the company's strategy regarding external partnerships and venture investments.